c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin–ATP-binding cassette G2 signaling

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome

(2011) Lijing Luo et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas

(2011) D. A. Zajchowski et al.   MOLECULAR CANCER THERAPEUTICS

Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells

(2011) J. M. Stewart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant

(2010) L Hu et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Multicellular spheroids in ovarian cancer metastases: Biology and pathology

(2009) Kristy Shield et al.   GYNECOLOGIC ONCOLOGY

A Wnt Survival Guide: From Flies to Human Disease

(2009) Andy J. Chien et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis

(2008) Daniela Matei et al.   CANCER

Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors

(2008) S. Zhang et al.   CANCER RESEARCH

Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects

(2008) Christoph Mundhenke et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

(2008) Russell J. Schilder et al.   JOURNAL OF CLINICAL ONCOLOGY